Oxidative stress (OS), when oxidative forces outweigh endogenous and nutritional antioxidant defenses, contributes to the pathophysiology of multiple sclerosis (MS). Evidence of OS is found during acute relapses, in active inflammatory lesions, and in chronic, longstanding plaques. OS results in both ongoing inflammation and neurodegeneration. Antioxidant therapies are a rational strategy for people with MS with all phenotypes and disease durations. PURPOSE OF REVIEW: To understand the function of OS in health and disease, to examine the contributions of OS to MS pathophysiology, and to review current evidence for the effects of selected antioxidant therapies in people with MS (PwMS) with a focus on lipoic acid (LA). RECENT FINDINGS: Studies of antioxidant interventions in both animal and in vivo models result in reductions in serum markers of OS and increases in levels and activity of antioxidant enzymes. Antioxidant trials in PwMS, while generally underpowered, detect short-term improvements in markers of OS and antioxidant defenses, and to a lesser extent, in clinical symptoms (fatigue, depression). The best evidence to date is a 2-year trial of LA in secondary progressive MS which demonstrated a significant reduction of whole-brain atrophy and trend toward improvement in walking speed. Antioxidant therapy is a promising approach to treat MS across the spectrum and duration of disease. Rigorous and well-powered trials are needed to determine their therapeutic benefits.
Keywords: Antioxidant; Lipoic acid; Multiple sclerosis; Neurodegeneration; Neurological disease; Neurology.
Mitoxantrone: a review of its use in multiple sclerosis.CNS Drugs. 2004;18(6):379-96. doi: 10.2165/00023210-200418060-00010. CNS Drugs. 2004. PMID: 15089110 Review.
Effect of lipoic acid consumption on oxidative stress among multiple sclerosis patients: a randomized controlled clinical trial.Nutr Neurosci. 2014 Jan;17(1):16-20. doi: 10.1179/1476830513Y.0000000060. Epub 2013 Nov 26. Nutr Neurosci. 2014. PMID: 23485514 Clinical Trial.
Therapeutic potential and biological role of endogenous antioxidant enzymes in multiple sclerosis pathology.Brain Res Rev. 2007 Dec;56(2):322-30. doi: 10.1016/j.brainresrev.2007.07.005. Epub 2007 Jul 27. Brain Res Rev. 2007. PMID: 17761296 Review.
New Insights into the Role of Oxidative Stress Mechanisms in the Pathophysiology and Treatment of Multiple Sclerosis.Oxid Med Cell Longev. 2016;2016:1973834. doi: 10.1155/2016/1973834. Epub 2016 Oct 18. Oxid Med Cell Longev. 2016. PMID: 27829982 Free PMC article. Review.
Early alpha-lipoic acid therapy protects from degeneration of the inner retinal layers and vision loss in an experimental autoimmune encephalomyelitis-optic neuritis model.J Neuroinflammation. 2018 Mar 7;15(1):71. doi: 10.1186/s12974-018-1111-y. J Neuroinflammation. 2018. PMID: 29514678 Free PMC article.
Cited by 2 articles
A Simplified Method for Simultaneous Determination of α-Lipoic Acid and Low-Molecular-Mass Thiols in Human Plasma.Int J Mol Sci. 2020 Feb 5;21(3):1049. doi: 10.3390/ijms21031049. Int J Mol Sci. 2020. PMID: 32033303 Free PMC article.
Redox phospholipidomics of enzymatically generated oxygenated phospholipids as specific signals of programmed cell death.Free Radic Biol Med. 2020 Feb 1;147:231-241. doi: 10.1016/j.freeradbiomed.2019.12.028. Epub 2019 Dec 25. Free Radic Biol Med. 2020. PMID: 31883467 Review.